Prof Schmid
Curigliano G et al. Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06). ASCO 2024;Abstract LBA1000.
Tarantino P et al. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Ann Oncol 2023;34(8):645-59. Abstract
Tarantino P et al. Navigating the HER2-low paradigm in breast oncology: New standards, future horizons. Cancer Discov 2022;12(9):2026-30. Abstract
Wolff AC et al. Human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2023;147(9):993-1000. Abstract
Dr Pegram
Bardia A et al. Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. N Engl J Med 2024;391(22):2110-22. Abstract
Bardia A et al. GS2-03 TRIO-US B-12 TALENT: Neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer. Cancer Res 2023;83(5_Supplement):GS2-03. Abstract
Cardoso F et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 2020;31(12):1623-49. Abstract
Fernandez AI et al. Examination of low HER2 expression in breast cancer. San Antonio Breast Cancer Symposium 2021;Abstract P1-02-02.
Jhaveri K et al. Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. Cancer Treat Rev 2024;123. Abstract
Mosele F et al. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: The phase 2 DAISY trial. Nat Med 2023;29(8):2110-20. Abstract
Powell CA et al. Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. ESMO Open 2022;7(4). Abstract
Slamon DJ et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244(4905):707-12. Abstract
Ueno N et al. Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician’s choice in HER2-low, hormone receptor–positive metastatic breast cancer in DESTINY-Breast04. ESMO 2024;Abstract 432P.
Vaz Batista M et al. Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: The DEBBRAH trial. ESMO Open 2024;9(9). Abstract
Viale G et al. Human epidermal growth factor receptor 2 (HER2)-low and HER2-ultralow status determination in tumors of patients (pts) with hormone receptor–positive (HR+) metastatic breast cancer (mBC) in DESTINY-Breast06 (DB-06). ESMO 2024;Abstract LBA21.
Dr O’Shaughnessy
Ciruelos E et al. Safety profile of trastuzumab deruxtecan in advanced breast cancer: Expert opinion on adverse event management. Clin Transl Oncol 2024;26(7):1539-48. Abstract
Tarantino P, Tolaney SM. Detecting and managing T-DXd-related interstitial lung disease: The five “S” rules. JCO Oncol Pract 2023;19(8):526-7. Abstract